Squarepoint
CVKD icon

Squarepoint’s Cadrenal Therapeutics CVKD Stock Holding History

Squarepoint’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13.4K Buy
+12,363
New +$22.4K ﹤0.01% 4344

Other funds holding CVKD

Courier Capital
Courier Capital Buffalo, New York $2.02B AUM 16.74% 1-Year Est. Return
Vectors Research Management
Vectors Research Management New York $362M AUM 21.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
Grove Bank & Trust
Grove Bank & Trust Miami, Florida $1.01B AUM 19.76% 1-Year Est. Return
Quest 10 Wealth Builders
Quest 10 Wealth Builders Fuquay-Varina, Virginia $135M AUM 16.01% 1-Year Est. Return
Archer Investment Corporation
Archer Investment Corporation Carmel, Indiana $545M AUM 21.2% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Squarepoint's CVKD Position: Q3 2026 in Review

Squarepoint opened a new position in Cadrenal Therapeutics (CVKD) in Q3 2026: 12,363 shares worth $13.4K. The stake represents ﹤0.01% of the portfolio and ranks #4344 among its holdings.

13 funds tracked by Wall St. Rank hold CVKD as of Q3 2026.

  • Squarepoint held 12,363 shares of Cadrenal Therapeutics worth $13.4K as of Q3 2026.
  • Cadrenal Therapeutics was a new Squarepoint position in Q3 2026.
  • Cadrenal Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4344 holding.
  • 13 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.